Navigation Links
DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
Date:3/11/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., March 11, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar"), a clinical and commercial stage drug development company with a focus on the treatment of cancer, today announced that Jeffrey Bacha , President & CEO of DelMar, will present at the ROTH 25th Annual Growth Stock Conference in Laguna Niguel, CA at 5:00pm PDT on Monday, March 18th, 2013.

"We are pleased to present the DelMar story at the ROTH Conference," said Jeffrey Bacha .  "This conference will complement our proactive program of investor communications and increase our awareness to the financial community as a new public company."

Mr. Bacha's presentation will be available on line at http://wsw.com/webcast/roth27/dmpi.t/

About DelMar Pharma
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989 or Booke & Company Investor Relations, admin@bookeandco.com.


'/>"/>
SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
2. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
5. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
6. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
7. Pipeline Initiatives, Partnerships to Drive Growth - Research Report on Pfizer, Theravance, ISIS Pharmaceuticals, Infinity Pharmaceuticals and Ironwood
8. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
9. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
10. Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
11. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017  AOTI Inc. announced today that its fully owned ... opened a New York City Office in Yonkers, New ... Topical Wound Oxygen (TWO 2 ) homecare therapy. This new East ... Health Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical ... Advanced Oxygen ...
(Date:8/10/2017)... -- Physical Rehabilitation Network (PRN), acquired the long-standing outpatient rehabilitation clinic, ... . The reputable clinic will continue to be co-owned and ... staff of four clinicians. Lipkin received his doctorate in physical ... years of experience with a strong background in manual therapy. ... 10th PRN clinic in and around the Denver ...
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
Breaking Medicine Technology:
(Date:8/19/2017)... , ... August 18, 2017 , ... Western University of ... and education to launch the University’s new Center for Innovation on Wednesday, September 6, ... Education Center Lecture Hall 1, followed by a technology exhibition from 1 to 3 ...
(Date:8/19/2017)... ... , ... Curl Keeper® is excited to announce that the H2O Water Bottle ... for the second year in a row. The H2O Bottle, a refillable ultra-fine spray ... Moisturizer for Type 2 Wavies and Best Refresher for Type 2 Wavies in 2017. ...
(Date:8/19/2017)... Orlando, Fla. (PRWEB) , ... August 19, 2017 ... ... that Taufiq Ahmed, M.D., has joined its Orlando location as an interventional pain ... in anesthesiology, a focus on the treatment of migraine headaches, and significant experience ...
(Date:8/18/2017)... ... August ... ... For Immediate Release                Contact: Julian Teixeira, August 18, ... Sex and Relationship Advice from their Fathers , Contrary ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces ... active, healthy lifestyles and highlighting the importance of proactive eye and ear health. ... shares the latest innovations in hearing aid technology. , In this issue, ...
Breaking Medicine News(10 mins):